Prestige in deal to market biosimilar Herceptin in Russia

Singapore’s Prestige BioPharma and privately-held Russian drugmaker Pharmapark have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige´s trastuzumab biosimilar in the Russian Federation.

Prestige´s trastuzumab is a biosimilar to Swiss pharma giant Roche’s (ROG: SIX) Herceptin, which is used to treat patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The product has recently been accepted for review at the European Medicines Agency (EMA), based on clinical results achieved with regard to the products´ safety and efficacy profile compared to Herceptin.

The deal comes hot on the heels of one with UK-based Mundipharma for Prestige’s Tuznue (trastuzumab) biosimilar certain European markets